Halozyme Therapeutics: Record Quarter Driven by High Licensing Revenues for Subcutaneous Administration

Halozyme Therapeutics develops technologies such as the proprietary enzyme rHuPH20 (ENHANZE platform), which convert intravenous medications for faster and easier subcutaneous injection. In response to the patent expiration of ENHANZE in 2029, management is forming new partnerships and introducing the new Hypercon technology. In the second quarter, the 50% increase in licensing business led to record revenues. With a P/E ratio of about 13, the stock is hitting new all-time highs. The biotech industry presents a unified bullish outlook...